Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynamically regulated by upstream regulatory element (URE), whose deletion causes downregulation of PU.1 leading to AML in mouse. In this study a significant group of the high-risk MDS patients, as well as MDS cell lines, displayed downregulation of PU.1 expression within CD34 þ cells, which was associated with DNA methylation of the URE. AZA treatment in vitro significantly demethylated URE, leading to upregulation of PU.1 followed by derepression of its transcriptional targets and onset of myeloid differentiation. Addition of colony-stimulating factors (CSFs; granulocyte-CSF, granulocyte --macrophage-CSF and macrophage-CSF) modulated AZA-mediated effects on reprogramming of histone modifications at the URE and cell differentiation outcome. Our data collectively support the importance of modifying the URE chromatin structure as a regulatory mechanism of AZA-mediated activation of PU.1 and induction of the myeloid program in MDS.
INTRODUCTION
Myeloid leukemia and myelodysplasia are considered a disorder of a hematopoietic progenitor that is unable to initiate and complete myeloid differentiation correctly, a process instructed by the Ets-transcription factor PU.1. 1 --5 Under normal conditions PU.1 recognizes a purine-rich motif/s and recruits additional factors 6 to dose-dependently guide hematopoietic differentiation and lineage commitment at specific gene promoters.
5,7 --9 PU.1 autostimulates its own expression directly via an upstream regulatory element (URE). 10, 11 URE is capable of loading the RNA polymerase II onto the PU.1 promoter 7,12,13 a process preceded by histone modifications (spanning more than 1 kb) at the URE. 7, 10 Thus the histone code of the PU.1 gene represents an important regulatory mechanism, which remains to be fully understood, to specify different cell fates such as macrophages, granulocytes and lymphocytes. 14 Genetic or epigenetic changes in the PU.1 gene frequently contribute to the pathogenesis of acute myelogenous leukemia (AML). First, deletion of URE in mouse resulted in a decrease of PU.1 to 20% and the onset of AML 12 documenting that PU.1 is a tumor suppressor. Second, mutations of PU.1 are associated with murine radiation-induced acute leukemia 15 or in rare cases of human AML. 16 --18 Third, integration of a viral DNA of Spleen Focus Forming Virus near URE in murine progenitors results in a state where PU.1 is unable to become upregulated to develop myeloid cells nor can it be silenced to develop red cells. 4,19 --22 Finally, PU.1 expression can be inhibited by a RNA interference mechanism via microRNA-155, which leads to a decreased protein synthesis of PU.1 and a block of terminal myelopoiesis. 23 Importantly, restoring PU.1 levels in acute leukemia as well as other hematologic malignancies induces cellular differentiation and cell cycle arrest. 4, 24 Changes in URE that result in lowered PU.1 expression levels are not only associated with AML pathology but also with multiple myeloma where the DNA methylation status of URE correlates also with increased tumor cell proliferation and shortened overall patient survival. 25 Treatment of multiple myeloma with DNA demethylating drugs is capable of upregulating PU.1 and induce a cell cycle arrest and apoptosis in myeloma cells in vitro. 25 Interestingly, other epigenetic therapy such as retinoic acid has been recently documented to upregulate PU.1 levels in acute promyelocytic leukemia. 26, 27 Collectively, these observations provide an important basis for developing epigenetic targets to manipulate PU.1 expression levels within hematological disorders.
The use of DNA methyl transferase inhibitors (DNMTi) in intermediate-2 (int-2)/high-risk MDS and some AML patients 28 --30 have doubled the overall survival with significant improvement in most of the clinical parameters (Fenaux et al. 31, 32 and reviewed in Quintas-Cardama et al.
33
). AZA affects DNA methylation status of the derepressed genes 34 and may also involve histone modifications.
--38
Epigenetic therapies may not simply block the tumor cell growth 39 but induce cellular differentiation. Recent findings indicated that normal murine and human CD34 þ progenitor cells treated with the DNMTi decitabine upregulated PU.1 expression by 150% and induced morphologic signs and gene expression pattern of terminal myeloid differentiation. 40 DNMTi may cooperate with colony-stimulating cytokines during induction of cell differentiation. Pre-stimulation of normal progenitors with granulocyte --colony-stimulating factor (G-CSF) prior the decitabine treatment in vitro enhanced myeloid differentiation. 40 Work acknowledged in this paragraph paved the way to develop the approach to increase PU.1 levels in MDS.
The understanding of how DNMTi function in MDS cells and whether their effect may be further enhanced by growth factors is incomplete. We herein present evidence that PU.1 expression is decreased in a significant proportion of int-2/high-risk MDS patients. We also show that AZA caused epigenetic reprogramming of the PU.1 gene resulting in the upregulation of PU.1 transcription and induction of cell differentiation. Effect of AZA is modulated by colony-stimulating cytokines. Understanding the prodifferentiation effects of AZA in MDS may add to a better understanding of heterogeneous patient outcome following the epigenetic therapy.
MATERIALS AND METHODS

Cell lines
Suspension cell lines (OCI-M2, SKM-1 all obtained from DSMZ, Braunschweig, Germany) were derived from MDS patients following transformation to AML. 41 We initially determined two sublethal concentrations of AZA (1 and 5 mM, freshly prepared every time) and used them as reported elsewhere. 34 Experimental design of AZA in vitro treatment was described previously 40 and consists of three doses of 1 or 5 mM AZA every 24 h and alternatively three doses of G-CSF 50 ng/ml (Neupogen, Amgen, Thousand Oaks, CA, USA) or granulocyte --macrophage (GM)-CSF 50 ng/ml or macrophage (M)-CSF 50 ng/ml (Sigma-Aldrich, St Louis, MO, USA, GM-CSF---cat. no. H5666-5 UG, lot: 041M1362; M-CSF---cat. no. SRP4237-10 UG, lot: 40737) added 6 h prior AZA.
Patients
Since 2006 we obtained bone marrow (and peripheral blood) samples from 44 patients (in 54 independent samples) with higher-risk MDS (IPSS int-2 and high risk) and AML; 32 males and 12 females, median age 67 years (range 57 --83 years). Diagnostic and prognostic evaluations were performed according to WHO guidelines (http://www.nccn.com): RAEB 1 (5 patients), RAEB 2 (17 patients), AML (with trilineage dysplasia) with 20 --30% blasts (12 patients), AML with trilineage dysplasia with 430% blasts (9 patients) and 1 patient with erythroleukemia. All samples were collected at the time of diagnosis and prior to any kind of treatment. All patients signed informed consent in accordance with the Declaration of Helsinki following institutional guidelines (see Supplementary Patient Material for clinical data and parameters). The cell samples were separated by Ficoll gradient (GE Healthcare, Pollards Wood, UK) followed by flow cytometry and sorting (BD FACSAria IIu, BD Biosciences, San Jose, CA, USA) or by magnetic sorting (AutoMACS, Miltenyi Biotec, Cologne, Germany) using antibodies to CD34 (clone 581/CD34 from BD Biosciences) and CD11b (clone M1/70 from BioLegend, San Diego, CA, USA). Cell culture of the cell lines was performed according to the manufacturer's recommendations; primary bone marrow cells were immediately cultured in IMDM (Iscove's Modified Dulbecco's Medium), 10% fetal bovine serum, non-essential amino acids, antibiotics, stem cell factor 20 ng/ml.
RNA expression
Total RNA was isolated by RiboZol (Amresco, Solon, OH, USA); analyzed by 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and reversetranscribed using High Capacity cDNA Reverse Transcription Kit with specific primers. Quantitative PCR (9700HT instrument) was run for 40 cycles, 95 1C/15 s---60 1C/60 s following the initial denaturation step using the TaqMan (Roche, Basel, Switzerland) probes. C t -values of specific (s) and control (c) amplicons served for calculation using 2 (ÀCTcÀCTs) equation. Student's t-test was also used for statistical analysis.
Immunoblotting
Primary cells or cell lines (0.5 to 1 Â 10 7 ) were lysed for 12 min in 200 ml RIPA buffer (50 mM Tris-HCl, pH 8.0; 137 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS; protease inhibitor cocktail P8340, Sigma) by vortexing four times for 20 s on ice followed by light sonication (50% amplitude, 3 cycles of 1,5 s pause in a cold room) on Branson Sonic Dismembrator (model 500) equipped with a micro tip. Denatured cell lysates (20 mg protein per lane) were resolved on 4 --12% gradient Bis-Tris gel (NuPage; Life Technologies, Carlsbad, CA, USA). The gels were dryblotted by iBlot Gel Transfer System (Invitrogen). Membranes were blocked by 7.5% nonfat milk in phosphate-buffered saline (0.1% Tween 20) . Anti-PU.1 [T-21] (1:600, sc-352; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody was used. Horseradish peroxidase-conjugated antibody was used to visualize bands using ECL Plus Western Blotting Detection System (GE Healthcare) on X-ray films. Anti-actin horseradish peroxidase-conjugated antibody (anti-actin [I-19] , sc-1616; Santa Cruz) was used to determine sample loading.
Chromatin immunoprecipitation
Cells (5 Â 10 6 ) were processed as described previously. 4 The following antibodies were used: H3K9acetyl (Upstate, Lake Placid, NY, USA, 07-352), H3K9trimethyl (Abcam, Cambridge, UK, 88-98), H3K4trimethyl (Diagenode, Lié ge, Belgium, pAb-003-050), and a control antibody (EMB Biosciences, San Diego, CA, USA, NI01). DNA from immunoprecipitates was measured by PCR on the independent amplicons (Supplementary Figure 1) upstream the PU.1 gene (À17.5 to À9.7 kb relative to the PU.1 transcription start site). These amplicons correspond to murine À14/À15 kb URE enhancer (h-17.5 and h-15.9), À12 kb enhancer (h-13.4), À10 kb enhancer (h-11) and À8 kb enhancer (h-9.7). Standard curves and DNA copy numbers were generated for all reactions. Protein occupancy on DNA ('percentage of input') is defined as a copy number of a specific DNA fragment in each immunoprecipitate compared with the copy number of that DNA fragment within 1/100 input dilution used for immunoprecipitation (1% input DNA). The control antibody values were subtracted from the values obtained using the specific antibodies.
DNA methylation analysis
Genomic DNA from the cell lines was subjected to bisulfite treatment using an EpiTect bisulfite kit (Qiagen, Venlo, The Netherlands). Bisulfite-treated DNA was then amplified with the primers 5 0 -GAGAAATGGTTTTTTTGT-GATTT-3 0 and 5 0 -ACAACTACCCCTATTTCCACAT-3 0 , encoding the 404-bp long region of PU.1 17-kb 5 0 upstream regulatory region and covering 19 CpGs of URE as published previously. 25 Amplified product was separated by agarose gel and purified by a QIAquick gel extraction kit (Qiagen). The PCR fragments were subcloned into a pCR 2.1-TOPO-vector (Invitrogen), then transfected into the chemically competent Escherichia coli strain TOP10. In average, 10 recombinant colonies were randomly chosen and plasmid DNA was isolated using Zyppy plasmid miniprep kit (ZymoResearch, Irvine-Orange, CA, USA). DNA sequencing was performed on a DNA sequencer ABI 3500 (Life Technologies) using a BigDye terminator cycle sequencing chemistry (Life Technologies).
RESULTS
Expression and epigenetic status of PU.1 gene in MDS progenitors and its response to AZA Given the importance of PU.1 in AML we set to determine whether its expression is dysregulated in other myeloid malignancies, namely MDS (see Supplementary Table with clinical data). We magnetically purified bone marrow CD34 þ population and observed that in comparison with healthy volunteers the PU.1 mRNA level is quite heterogeneously distributed among MDS patients ( þ 2 to À2 shown in log2 scale in Figure 1a) . Levels of the normalization factors (G6PD, HPRT1 or GAPDH) did not display such fluctuation. As lower levels of PU.1 transcripts correlate with the onset of AML, we focused on the MDS patients that displayed markedly lower PU.1 levels compared with normal controls.
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The expression of PU.1 in primary MDS CD34 þ progenitors allowed us to categorize the patients into two distinct groups with either low (below average plus standard error of control CD34 þ cells) or int-2/high PU.1 expression. Despite limited number of the patients (N ¼ 17) we observed significant trend toward increased survival on AZA in patients with PU.1 int-2/high levels ( Figure 1b) .
To study the mechanism behind downregulated PU.1 expression in MDS progenitors, we measured the DNA methylation status at the URE (19 CpGs, approximately À17 kb region, see Supplementary Figure 2B ) within OCI-M2 cells. This cell line represents an AML transformation of high-risk MDS and expresses low PU.1 transcripts at levels similar to those measured within our MDS-PU.1 low population (Figure 1a ). The URE in OCI-M2 is heavily methylated with maximum at CpGs 3 --5 and 13 --16 (Supplementary Figure 2A ). It should be noted that these CpGs neighbor the PU.1 and AML1 binding sites required for PU.1 autoregulatory stimulation.
To address whether the DNA methylation can be reduced by DNMTi, we treated OCI-M2 cells with AZA (see Materials and Methods section). AZA caused a dose-dependent decrease of DNA methylation of URE (Figure 1c ). It should be noted that within the AML1 and PU.1 binding regions AZA treatment had little effect upon DNA demethylation of the CpG 14, while other CpGs 11,13,15,16,19 of these binding regions are significantly demethylated.
Our data show that high-risk MDS patients underexpressing PU.1 displayed shorter survival on AZA therapy and that in a model cell line OCI-M2 low levels of PU.1 transcripts are associated with high degree of DNA methylation at URE that can be significantly reduced by AZA treatment.
PU.1 mRNA and protein are induced by AZA in MDS cells resulting in differentiation To determine whether there is a direct correlation between URE methylation and regulation of PU.1 transcripts, we studied the effect of AZA treatment upon PU.1 expression. Indeed, AZA treatment of OCI-M2 upregulated PU.1 at both mRNA ( Figure 2a ) and protein (Figure 2b) . Furthermore, AZA treatment induced the transcriptional program of PU.1 target genes with marked upregulation of CSF3R, EGR2, FOS, GELB, CEBPA, CSF1R and MPO (Figure 2c ). To determine whether the induction of the PU.1 transcriptional network was sufficient to induce cellular differentiation, we used flow cytometry analysis using antibody to CD11b. Indeed, AZA-induced protein expression of CD11b (table attached below Figure 2a ) showed a trend r ¼ À0.37 of negative correlation between PU.1 expression and DNA methylation at URE (Figure 2e ). These data also indicated that OCI-M2 cells represent very unique model that shows striking similarities with the primary progenitor cells derived from int2/high-risk MDS patients.
This paragraph shows that PU.1 expression is related to methylation status of URE and that AZA upregulates PU.1 coincidently with DNA demethylation of URE in MDS cells.
Myeloid colony-stimulating cytokines modulate AZA-mediated effects on MDS cells via chromatin modifications at URE On the basis of a previous study in which G-CSF potentiated PU.1 upregulation and myeloid differentiation within normal human CD34 þ progenitors, 40 we asked if this treatment could be utilized in MDS cells. We used the OCI-M2 cells as our model system and included M-CSF and GM-CSF to determine whether the cell-stage specificity of the MDS progenitors could be differentially sensitive to any cytokine-mediated effects.
Interestingly, all cytokines enhanced significantly AZA-mediated DNA demethylation of URE (Supplementary Figure 2A) . This was associated with derepression of PU.1 (and its target EGR2) in the cells co-treated with GM-CSF and M-CSF (Figure 3a) . Notably, G-CSF mildly reduced the AZA-mediated PU.1 induction coinciding with a dampering of the EGR2 response. Despite both M-CSF and GM-CSF augmenting the AZA effect, only in the GM-CSF/AZAtreated cells was the cell differentiation effectively induced as demonstrated by expression of CD11b using flow cytometry ( Figure 3b ) coincidently with a block of cell proliferation (Figure 3c ). The apoptosis did not significantly differ between cells either treated with AZA or AZA in combination with the cytokines.
In order to understand the consequences that AZA and the cytokines treatments have on the URE, we have performed detailed analysis of histone modifications at URE in the OCI-M2 (Figure 3d ). We have used amplicons at URE and other enhancers; however, for a concise presentation of the data only three amplicons are shown (À17.5, À16.6 and À15.9 kb upstream the PU.1 gene start site). Chromatin immunoprecipitation analysis of an active chromatin mark, histone H3 lysine (K)4 triMethylation (H3K4Me3), indicated its increase at URE following AZA exposure. The combination of AZA with GM-CSF or M-CSF did not significantly change the H3K4Me3 profile at the URE, while with G-CSF caused a decrease compared with AZA alone (Figure 3d, left  panel) . Next, we investigated another active mark H3K9 acetylation (H3K9Ac) at PU.1 gene by chromatin immunoprecipitation. Interestingly, while AZA/G-CSF combination caused increase of H3K9Ac downstream URE (at À15.9 amplicon), the AZA/GM-CSF combination appeared to increase H3K9Ac at the URE (À16.6 kb) and this was associated with the most prominent effect on PU.1 level (Figure 4d, right panel) .
Thus, use of colony-stimulating cytokines preceding addition of AZA to MDS cells facilitated changes in DNA demethylation as well as histone modifications at URE resulting in more efficient PU.1 derepression.
Primary MDS progenitors respond to AZA by inducing myeloid differentiation Our data implicate AZA as a potent agent in restoring the myeloid differentiation capacity of MDS CD34 þ progenitors. To explore this further, we have studied int-2/high-risk MDS patients in detail on both the chromatin and expression levels (see Supplementary  Table) and determined in vitro response to AZA in the presence or absence of colony-stimulating cytokines. G-CSF was used as it was shown to potentiate expression of PU.1 by DNMTi 40 and is routinely used in clinical hematology. For such studies we have used ex vivo isolated bone marrow-derived progenitors of the patient P302, a 67-year-old male with RAEB II (WHO), IPSS-Int2, who presented with anemia and transfusion dependency of 4 TU/Mo, neutropenia and 10% blasts in bone marrow (phenotypically characterized as CD33 þ CD34 þ CD117 þ HLADR þ CD45 þ that were also detectable in peripheral blood by flow cytometry). Additionally, we also studied patients P301 (76-year-old male, with RAEB II) and P299 (69-year-old male with RAEB-T). All three (Figure 4a) . Importantly, PU.1 transcript expression (in P302) was responsive to AZA treatment and this effect was enhanced by preincubation with myeloid colony-stimulating cytokine G-CSF (Figure 4b ). PU.1 target gene CSF1R was also upregulated by AZA and AZA/G-CSF (Figure 4c) . Importantly, incubation of MDS cells with AZA and G-CSF significantly downregulated expression of KIT, a known stem cell marker (Figure 4c ). This phenomenon was also observed in the OCI-M2 cells (Figure 4d ) again demonstrating similarity of the MDS patients and the OCI-M2 cells. The flow cytometry experiments indicated that the patient P302 decreased CD34 positivity and gained CD11b positivity following AZA/G-CSF (Figure 4e ). We have observed enhanced CD11b expression following in vitro AZA/G-CSF treatment also in the patients P299 and P301 (data not shown). Chromatin immunoprecipitation indicates that at the URE the AZA treatment (and this was potentiated by G-CSF) significantly changed the histone modification pattern: it increased H3K9Ac and decreased H3K9Me3 coincidently with PU.1 gene derepression (Figure 4f ).
Activation of PU.1 gene by AZA involves also other regulatory regions in addition to URE To determine whether AZA-mediated upregulation of PU.1 is solely dependent upon the URE, we utilized UREÀ/À mutant mice. 12 As previously described these mice develop AML due to the dysregulation of PU.1 expression. AML progenitors derived from bone marrow were magnetically sorted for c-kit positivity as described previously. 12 The progenitor cells were in vitro treated by AZA (as outlined above) and mRNA of PU.1 and its targets and control genes were subsequently determined ( Figure 5 ). Our data confirmed that PU.1 levels in blast-AML of UREÀ/À mice are approximately fivefold downregulated as compared with the control c-kit-positive normal bone marrow progenitor cells. In the absence of the URE, the PU.1 transcripts were induced in a dose-dependent manner by AZA treatment in a similar relative fold change as in control progenitors. The levels of PU.1 were reflected by levels of PU.1 targets Egr2 and Gfi1 in the same samples.
These data indicate that even though URE is required for expression of physiological levels of PU.1 it is not exclusively required for AZA-mediated upregulation of PU.1 levels in AML.
Thus, effect of AZA treatment is in addition of URE dependent on another enhancer regions or the promoter itself.
DISCUSSION
Current therapeutic treatment of hematologic malignancies focuses on the need to induce apoptosis and/or cycle arrest of the malignant cell population. However, the ability to restore and induce cellular differentiation represents an alternate strategy, and has potential to be very helpful in the treatment of diseases that are often refractory to standard chemotherapy regimens. We herein present new evidence that gene encoding a key hematopoietic transcription factor PU.1 is a target of chromatin modifications mediated by AZA in MDS. 12 or control mice (right) were subject to reverse transcription --PCR analyses following AZA (1 and 5 mM) treatment for 72 h in three doses (Materials and Methods). Expression of PU.1, Egr2 and Gfi1 at 72 h is relative to Gapdh mRNA determined in the same samples. Fold change relative to untreated cells is indicated on top of the columns.
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We initially determined expression of PU.1 in CD34 þ cells of MDS patients with higher risk and found that among patients with significantly shorter survival on AZA are patients with low expression of PU.1 (Figure 1 ). In addition, expression of PU.1 negatively correlated with DNA methylation at URE. Presence of a relatively stable repressive mark such as DNA methylation and H3K9Me3 at URE in the higher risk MDS progenitors indicates that repression of URE may represent an important barrier of PU.1 autoregulation mechanism and that it can be reverted by AZA. Specifically, our data strongly indicate that MDS progenitors with heavily repressed URE would require higher dose of AZA and those that display relatively open URE chromatin may require lower dose of AZA. Importantly, AZA in order to activate PU.1 gene expression may target additional regulatory regions, other than URE ( Figure 5) . Therefore, more patient data and analyses of the PU.1 upstream regions are however needed to fully comprehend the relationship between the epigenetic status of PU.1 gene and clinical responsiveness to AZA.
Alternatively to recommending different AZA levels, we searched for mechanism that would enhance AZA-mediated effects on PU.1 gene and focused on colony-stimulating cytokines such as G-CSF. It is important to note that additional chromatin modifiers may be required in order to achieve PU.1 gene reexpression outcome following DNA demethylation in MDS. 42 G-CSF was shown to facilitate repression of stem cell genes with or without its direct effect to induce PU.1 expression as reported elsewhere. 40 Others reported that addition of DNMTi to normal murine progenitors preceded by G-CSF (or transgenic activation of PU.1) upregulated PU.1 levels and its program of myeloid differentiation. 40 Our data in primary MDS progenitors (Figure 4c ) and OCI-M2 cells (Figure 4d ) indicated that indeed G-CSF inhibited AZA-mediated induction of KIT expression coincident with enhanced myeloid differentiation. Our data also indicate that G-CSF (and also GM-CSF and M-CSF) preincubation prior AZA is capable to influence both DNA methylation (Figure 1c and Supplementary Figure 2) and chromatin modifications at URE (Figures 3 and 4) , is associated with increased PU.1 mRNA levels and may be mediated by G-CSF signaling pathway that includes PU.1. It should be noted that AZA alone and importantly together with G-CSF is capable to recapitulate its effects observed in the MDS cell line, also in ex vivo isolated primary high-risk MDS cells. G-CSF represents a cytokine that is frequently used in MDS and AML and other hematological malignancies to prevent neutropenic complications following chemotherapy. 43 Its use in MDS is not associated with increased frequency of developing AML 44, thus it represents promising candidate with a potential to augment AZA prodifferentiation effects.
We observed that some patients whose tumor cells expressed higher PU.1 level displayed favorable therapeutic response; such observation will require extended follow-up and analyses of additional patients. If this scenario is however correct, further assessment of molecular response to AZA and AZA/ G-CSF will be crucial in predicting responsiveness to AZA, potential of AML transformation and other phenotypic features of high-risk MDS. Responsiveness of MDS cells to G-CSF pretreatment prior to AZA in vitro may provide rationale for further evaluating the role of G-CSF in addition to epigenetic therapy in MDS going forward.
